Dyne has built a focused pipeline with lead programs in myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), both with FDA Breakthrough Therapy designations. The company is positioned for commercialization with a planned launch in early 2027 and cash runway extended to Q3 2027 following a $350M equity raise.
Cyborg Score Rationale
Dyne demonstrates strong clinical progress with FDA validation (Breakthrough Therapy designations, positive feedback on registrational pathways) and prudent capital management via recent $350M raise. Risk remains in clinical execution and the company is pre-revenue.
Top Insights
FDA granted positive feedback enabling registrational cohort for z-basivarsen in DM1 with potential Accelerated Approval using video hand opening time as intermediate endpoint
Lead programs (DYNE-101 for DM1, DYNE-251 for DMD) both carry FDA Breakthrough Therapy and Orphan Drug designations, suggesting high unmet need and expedited review potential
$350M equity raise in December 2025 extends cash runway beyond multiple inflection points including Q3 2027, past planned early 2027 commercial launch
Company building commercial infrastructure and manufacturing capabilities in preparation for potential product launches in rare disease space
Named Competitors
Genetic therapies for muscular dystrophy — Muscle-targeted gene therapy platform
Antisense therapeutics for neuromuscular disease — Wave platform for genetic diseases
Gene therapy and small molecule programs — Neuromuscular disease therapeutics